Objectives-To test the hypothesis of a diurnal variation in circulating levels of interleukin-6 (IL-6) and/or tumour necrosis factor-alpha (TNF-alpha) in rheumatoid arthritis and other inflammatory connective tissue diseases.
stantially increased in patients with rheumatoid arthritis. Furthermore, patients with rheumatoid arthritis showed a statistically significant circadian variation in levels of IL-6. Peak values appeared in the morning and low values in the afternoon and evening. In contrast, levels were low and stable in other connective tissue diseases. Levels of TNF-alpha were low in patients with rheumatoid arthritis and high in patients with other connective tissue diseases, but without circadian rhythm. After treatment with prednisolone, levels of serum IL-6 decreased significantly, but the circadian rhythm remained.
Conclusions-The circadian rhythm of circulating IL-6 might correspond to the circadian rhythm of symptoms in rheumatoid arthritis. The diurnal variation of IL-6, and possibly other cytokines, might explain the conflicting results previously reported on the inter-relationship between circulating IL-6 levels and disease activity in rheumatoid arthritis.
(Ann Rheum Dis 1994; 53: 521-524)
The appearance of pro-inflammatory cytokines in joint tissue/synovial fluid and serum/plasma of patients with arthritic conditions, suggests that they play a role in the local and systemic inflammatory responses. However, in many clinical studies it has not been possible to relate known in vitro effects of pro-inflammatory cytokines to clinical and laboratory observations. IL-6 mediates the synthesis of acute phase proteins.' Substantially increased concentrations of IL-6 have been reported in synovial fluid and serum/plasma from patients with rheumatoid arthritis.4-10 In some studies, a correlation was found between serum/ synovial fluid IL-6 levels and parameters of disease activity in rheumatoid arthritis. 3 The first blood sample was drawn at 7:30 after overnight fasting and while the patient was still in bed. Thereafter blood samples were collected at 10:30, 13:30, 16:30, 19:30 and 22:30. The serum samples were stored for one hour at room temperature, centrifuged at room temperature and aliquoted before being stored at -70°C for later analysis of IL-6 and TNFalpha. Furthermore, the first morning sample at 7:30 was analysed for the following: haemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum haptoglobin, white blood cell and platelet count.
The effects of a potent anti-inflammatory treatment on the serum levels of IL-6 and TNF-alpha in patients with rheumatoid arthritis were also studied. Therefore a second set of blood samples was drawn from four patients after one week of treatment with the glucocorticoid prednisolone (15-20 mg daily).
CYTOKINE ANALYSIS
The levels of free human IL-6 and TNF-alpha in serum were measured using commercial ELISA-type kits (MEDGENIX Diagnostics, Brussels, Belgium). The two tests were based on solid phase enzyme amplified sensitivity immunoassay technique (EASIA). They were performed in microtitre plates using several monoclonal antibodies directed against distinct epitopes on the two molecules. Purified recombinant human IL-6 and TNF-alpha were used as standards. The lowest standard point for the IL-6 assay was 20 pg/ml while the minimum detectable concentration was estimated to be 3 pg/ml. The corresponding figures for the TNF-alpha assay were 15 pg/ml and 3 pg/ml, respectively. The IL-6 EASIA was shown not to cross-react with IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, GM-CSF, IFN-alpha and gamma, TNF-alpha and beta, while the TNF-alpha assay was shown not to cross-react with TNF-beta, IL-1, IL-2, IFN-alpha, beta and gamma as specified by the manufacturer. (fig 2) .
TUMOUR NECROSIS FACTOR-ALPHA
The serum levels of TNF-alpha did not show any significant differences during the day in any of the patient groups. In contrast to the IL-6 levels, the serum levels of TNF-alpha were lower in patients with rheumatoid arthritis compared with the other patient groups (fig 3 and table 3 ).
In patients with RA, significant correlations were found between the calculated total amount of serum IL-6 during the day (area under the curve) and the platelet count (r = 0 6; p < 0 01), and between the maximum IL-6 value in the morning and the platelet count (r = 0 7; p < 0.01). No correlation was found between morning serum levels of IL-6 or calculated IL-6 area under the curve and clinical indices of disease activity such as morning stiffness, joint pain score or Ritchie's index in patients with rheumatoid arthritis, nor was there any correlation with laboratory parameters of disease activity such as ESR, CRP or haptoglobin. However, when all arthritic patients were included in the calculations, the maximum IL-6 levels in the morning correlated to Ritchie's index (r = 0 5; p < 005) and CRP (r = 0-4; p < 0-05). Non-RA arthritides (10) 7 (4) 8 (5) 7 (4) 6 (4) 6 (4) 6 (4) SSc (13) 18 (4) 18 (5) 18 (5) 17 (4) 19 (5) 18 (4) SLE (7) 29 (12) 30 (12) 28 (12) 24 (11) 29 (12) 17 (6) 
Discussion
Our findings demonstrate that the circulating levels of IL-6 are increased in the morning in patients with rheumatoid arthritis and decline significantly from early in the afternoon to late in the evening. On the contrary, the circulating levels of TNF-alpha were not increased and remained stable during the day. In other inflammatory connective tissue diseases like systemic lupus erythematosus, systemic sclerosis, primary Sjogren's syndrome and mixed connective tissue disease, the IL-6 levels were low while the TNF-alpha levels were increased but without diurnal variation. The synovial fluid in rheumatoid arthritis contains substantially increased amounts of IL-6 and more modestly increased amounts of TNF-alpha.2 5 " Using cytokine probes, it has been claimed that IL-6 in rheumatic synovial fluid originates from type B synovial lining cells and fibroblasts.' 18 19 It is uncertain to what extent the locally produced IL-6 contributes to the circulating levels of IL-6 in rheumatoid arthritis. However, it is reasonable to assume that a considerable amount of IL-6 is transported from the joint tissue to the general 
